The FDA's Pharmacy Compounding Advisory Committee voted on July 23–24, 2026 to recommend that six out of seven peptides be added to the list of compounds that state-licensed pharmacies can legally prepare for patients. The compounds — including BPC-157, KPV, TB-500, and MOTS-c — are currently sold on the gray market as "research use only" products. The FDA's own career scientists had recommended against adding any of them, citing a lack of robust human clinical trials. The committee vote is advisory only; the FDA isn't required to follow it, and formal rulemaking to actually change compounding rules could stretch to 2028 or later.

1. Patients Need Access, and Compounding Adds Oversight (HHS Secretary RFK Jr., Asare Christian MD)

Millions of Americans are already using these compounds — legalizing compounding just adds a doctor to the equation.

Restricting compounding hasn't stopped anyone. Millions of Americans buy these peptides from gray-market vendors with no physician involved. If the FDA adds them to the compounding list, patients would still need a prescription — that's actually more medical oversight than exists now. HHS Secretary Robert F. Kennedy Jr. made this the centerpiece of his push, announcing in February 2026 that he intended to move most restricted peptides back to legal compounding status.

Millions are already using these compounds. Asare Christian, MD, the founder of Aether Medicine wellness clinic and one of eight new temporary committee members, voted yes and said the vote gives researchers "better opportunities to characterize it, study it, and potentially present this to patients." He argued the committee's job wasn't to adjudicate unresolved efficacy questions — it was to decide whether access made sense given what's known.

The gray market is large and growing. Crypto payments to gray-market peptide vendors totaled $32 million in the first quarter of 2026 alone. David Pope, chief pharmacy officer of XiFin Pharmacy Solutions and a yes vote on most compounds, said he voted because "it's time to put this decision back in the hands of the patient, the physician and the pharmacist."

2. But There Are No Human Trials (Elizabeth Rebello, Mary Thanh Hai, FDA Staff)

These compounds have real-world popularity but no rigorous clinical evidence in humans — and that gap is the whole problem.

Popularity isn't the same as proven safety. Researchers have run most BPC-157 studies in rodents, not people. The FDA's career staff found no large, well-controlled human trials demonstrating that these peptides are safe or effective. Elizabeth Rebello, a professor in anesthesiology at UT MD Anderson Cancer Center and a no vote, cited the "lack of efficacy data and randomized controlled trials" as disqualifying.

Without human-trial data, doctors are operating blind. Mary Thanh Hai, director of the FDA Office of New Drugs, warned that adverse events from gray-market products never make it back to regulators — so even the injury data is thin. Bill Zamboni, a committee member and no vote, said simply: "There are too many unknowns about this product." FDA staff member Russell Wesdyk said the agency can't even establish consistent quality standards for BPC-157 because the compound itself isn't well-characterized enough.

BPC-157 and TB-500 are both on the World Anti-Doping Agency's prohibited list. The FDA has only three adverse event reports on file for BPC-157 — injection site reactions and shortness of breath — and those are difficult to interpret because of incomplete data.

3. And the Committee Was Stacked (AP Reporting, Critics of Committee Composition)

Critics say RFK Jr. built this committee to reach this result.

RFK Jr. rebuilt the advisory committee before this vote. He added eight temporary members in June 2026. According to the Associated Press, those members include doctors and pharmacists who run peptide clinics, sell peptide injections, or promote the substances online. Every single one of those eight new members voted yes on all four compounds reviewed on Day 1. The meeting room responded with an audible gasp when the tally came in.

The vote split exactly along appointment lines. The six non-newly-appointed committee members voted no. All eight new MAHA-appointed members voted yes. That's not a close call on the first day's compounds; it was a unanimous 8-for-8 from one side of a politically reconstituted panel.

The FDA doesn't have to follow this recommendation. But the political pressure it creates is real. Catherine Ebeling, writing for the MAHA Report, called the vote "a win for HHS Secretary Kennedy and MAHA."

Where This Lands

MAHA advocates say millions of Americans are already using these compounds, and that compounding pharmacies would add medical oversight to an unregulated gray market. FDA scientists say there's no human clinical evidence that any of these peptides are safe or effective — and that doctors prescribing them will have nothing real to go on. The harshest critics say the compounds' merit barely matters: RFK Jr. built that committee, member by member, to reach this conclusion. The FDA can reject the recommendation — but the agency that would do so is led by the same people who pushed for it.

Sources